YES Securities is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1015 in its research report dated October 24 2023.
The company reported a 37 percent YoY increase in net profit at RS 33 crore and a revenue of Rs 483.5 crore, a 13.7 percent growth in the July-to-September quarter
NCC has seen a breakout of nearly a month-long consolidation and formed strong bullish candlestick pattern on the daily scale with robust volumes. In fact, the trading volume was highest since January 2 this year.
KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 982 in its research report dated August 01, 2023.